Introduction
Vascular endothelial growth factor (VEGF) is an angiogenesis regulatory factor and endothelial cellspeci®c mitogen (Leung et al., 1989; Keck et al., 1989) . Many evidences indicate that VEGF is regulated by hypoxia in vivo and in vitro (Shweiki et al., 1992; Minchenko et al., 1994) . The hypoxia-induced increase of VEGF gene expression is due to both transcriptional activation of corresponding gene and by increased stability of VEGF mRNA (Ikeda et al., 1995) .
In addition to VEGF, hypoxia is known to upregulate the expression of several genes such as those encoding erythropoietin (Epo) (Krantz, 1991) , phosphoglycerate kinase 1, and lactate dehydrogenase A gene (Frith et al., 1994) . Epo and VEGF gene expressions are signi®cantly up-regulated not only during hypoxia but also, by cobalt chloride, while it is inhibited by carbon monoxide (Goldberg and Schneider, 1994) . These results suggest similarities between oxygen-sensing mechanisms that regulate expression of both these genes (Goldberg and Schneider, 1994) . Computer analysis has revealed two 10-base pair sequences located 5' to the human VEGF gene transcription start site which are 90% homologous to a sequence element located within the human Epo 3' hypoxia-responsive enhancer (Beck et al., 1991; Blanchard et al., 1992; Semenza and Wang, 1992; Madan and Curtin, 1993) . Furthermore, the rat VEGF 5'-¯anking sequence shares elements homologous to the hypoxia-inducible factor 1 (HIF-1) binding site (Levy et al., 1995) , a regulatory element that is recognized by protein(s) that speci®cally bind to an enhancer element located 3' to the Epo gene in a hypoxia-regulated fashion (Semenza and Wang, 1992; Wang and Semenza, 1993) . Taken together, these observations suggest that expression of Epo and VEGF genes are likely to be responsive to common oxygen-sensor and oxygen-sensing pathways. NO is known to be a diversely functioning physiological mediator and generated from L-arginine (L-Arg) by nitric oxide synthase (NOS) in many dierent cell types. Ohigashi et al. (1993) demonstrated that (L)-N G -nitroarginine methyl ester (L-NAME), a NOS inhibitor, inhibited both cyclic 3', 5'-guanosine monophosphate (cGMP) generation and Epo production in response to hypoxia, and suggested that NO synthesis is essential for hypoxic stimulation of Epo production. But little is known about the relationship between NO and VEGF. Starting from these observations, we hypothesized that NO could regulate also expression of the VEGF gene. Glioblastoma multiforme, a malignant human primary intracranial brain neoplasm, is known to present elevated expression of VEGF in the periphery of its necrotic area (Plate et al., 1992; Shweiki et al., 1992) and VEGF is essential for its growth (Millauer et al., 1994) . In this report we evaluated the eect of NO on VEGF gene expression in A-172 human glioblastoma cells and human HepG2 hepatocellular carcinoma cells as models.
Results

Signi®cant increase of VEGF mRNA expression in A-172 and HepG2 cells following treatment with NO donors
We detected 3.7 kb and 4.4 kb VEGF message in RNA prepared from A-172 and HepG2 cells. In A-172 cells, as shown in Figure 1a , both VEGF mRNA species were dramatically induced following treatment with 0.5 mM SNAP. Increased mRNA levels were observed as early as 2 h after addition of SNAP, and reached the maximum levels after 4 to 8 h of treatment to decline to about 60% of the maximum by 24 h (Figure 1a ). When we examined the eect of SNAP on VEGF mRNA expression in HepG2 cells, results were comparable. Maximal induction of VEGF mRNA was detected in this case after 12 to 24 h of SNAP treatment (Figure 1b) . In A-172 cells, maximal VEGF mRNA expression was observed after 6 h with 0.5 mM SNAP by about 11 and 8 fold respectively (Figure 2 ), although as little as 0.1 mM SNAP was sucient to induce accumulation of VEGF mRNA. Higher doses of SNAP, at and above 1.0 mM, were less eective in inducing VEGF mRNA expression. VEGF mRNA increase was also observed following A-172 cell stimulation with NOR3, another chemical NO generator, but not with acetylpenicillamine, a non-NO generating analogue of SNAP (Figure 3 ). These results indicate that NO itself is likely to induce VEGF mRNA expression in both A-172 and HepG2 cells.
Involvement of guanylate cyclase in NO-mediated increase of VEGF gene expression
To investigate the signal transduction pathway(s) mediating the increase of VEGF mRNA expression occurring in response to SNAP in A-172 cells, we examined the eects of herbimycin A, methylene blue, LY-83583 and staurosporine co-treatment on this parameter. VEGF mRNA induction by SNAP was completely inhibited by 10 mM methylene blue ( Figure  4a ) as well as by 1 mM LY-83583 (Figure 4b ), but not by staurosporine (1 ± 50 nM) or herbimycin A (0.001 ± 0.1 mg/ml) (Figure 4c and d) . These results indicate that guanylate cyclase activity is involved in NOmediated induction of VEGF gene expression, whereas protein kinase C or tyrosine kinase activities are not.
VEGF mRNA accumulation in response to NO is inhibited by cycloheximide
To clarify whether newly synthesized proteins are necessary for stimulation of VEGF expression, the eects of the protein synthesis inhibitor, cycloheximide, was examined in A-172 cells. Cycloheximide at 25 mg/ ml was sucient to inhibit VEGF mRNA accumulation in response to SNAP ( Figure 5 ), indicating that new protein synthesis is required for NO-mediating induction of VEGF mRNA.
NO increases VEGF mRNA stability
To evaluate the eect of SNAP on VEGF mRNA stability, we measured the half-lives of VEGF mRNA in A-172 cells in the presence or absence of NO donor. Following 6 h treatment of the cultures with or without 0.5 mM of SNAP, 25 mg/ml of actinomycin D was added to the medium to block further gene transcription and the rate of VEGF mRNA decay was then measured by Northern blot analysis. As shown in 
NO increases VEGF protein level in A-172 cells
In order to con®rm that increase in VEGF mRNA levels in A-172 cells caused by NO treatment coincided with increase in VEGF protein production, we examined VEGF protein levels in A-172 cells and its culture medium. The antibody against VEGF recognized three bands in treated culture medium with molecular masses of about 24, 22, and 20.5 kDa, respectively as shown in Figure 7 . Trace amount of VEGF protein was detected in untreated cell culture medium but the amount of VEGF remarkably increased upon NO treatment ( Figure 7 ). Compared to the amount of VEGF in the culture medium, cellular content of VEGF protein were much less throughout the treatment period indicating relatively rapid secretion of VEGF (data not shown). VEGF protein isolated from various cell sources has been reported to 
Discussion
One of the main biological roles of NO is maintaining relaxation of blood vessel but the full eects of NO on angiogenesis have not been fully understood to date although some reports indirectly suggest that NO may be involved in angiogenesis. The NO-generating drugs nitroglycerin (NTG) and L-arginine facilitate healing of experimental gastric ulcer induced by acetic acid (Konturek et al., 1993) . During this process, angiogenesis appears to be increased by administration of exogenous NO donor. Ziche et al. (1993) reported that 10 mM sodium nitroprusside treatment increases [ 3 H]-thymidine incorporation in endothelial cells isolated from bovine coronary postcapillary venules, while methylene blue treatment selectively reduces this eect. These results suggest that NO production can exert a proliferative eect on endothelial cells at microvascular level, mediated by guanylate cyclase activation.
In this report we show that treatment with a NO donor SNAP increases both VEGF mRNA expression and proteins in A-172 and HepG2 cells (Figures 1, 2  and 7 ). The induction of VEGF mRNA was achieved not only by SNAP but also by a structurally dierent NOR3 but not by the non-NO-generating SNAP analogue acetylpenicillamine (Figure 3) . These results indicate that NO can induce increase of VEGF gene expression in A-172 cells. This is the ®rst demonstration that VEGF expression is induced by NO. Moreover, the evidence that VEGF induction by SNAP can be observed in two cell lines indicate that this is possibly general response of various cell types to NO.
The NO-induced increase VEGF mRNA level in A-172 cells was accompanied by increased mRNA stability ( Figure 6 ). However, while VEGF mRNA accumulation following 6 h exposure to SNAP was quite signi®cant about 10 times higher than in the controls, increase in mRNA stability under the same conditions was limited (only 2.4 fold). This dierence could suggest that transcriptional activation of the VEGF gene is also involved (Figures 1 and 6) .
When oxygen demand in a given tissue is higher than its supply, blood¯ow must increase locally to match the increased need. Vasodilatation must be one of the mechanisms that follow acute increases of blood ow. Endothelium derived relaxing factor (EDRF) has been suggested to play a coordinating role in local blood¯ow regulation and is NO itself (Palmer et al., 1987) . Pohl and Busse (1989) reported that a reduction in the partial pressure of oxygen stimulated the rapid release of EDRF from native and cultured endothelial cells, and this can, temporarily, reduce tissue hypoxia. But if tissue hypoxia is not fully corrected and continues in spite of vasodilatation, compensatory angiogenesis must occur. Angiogenesis is stimulated by hypoxic conditions (Adir et al., 1990) . In the regulation of this process, several growth factors such as ®broblast growth factors, transforming growth factor-b (TGF-b) and VEGF are considered to be involved (Folkman and Klagsbrun, 1987; Risau, 1990) . VEGF has been recognized as an important angiogenesis factor during hypoxia-induced angiogenesis (Dvorak et al., 1995; Shweiki et al., 1992) and Ku et al. (1993) showed that VEGF induces EDRFdependent relaxation in coronary arteries. It seems quite reasonable that NO and VEGF cooperate to correct and prevent hypoxia. Tuder et al. (1995) reported that sodium nitroprusside (10 74 M) decreased VEGF and VEGF receptor mRNA levels in isolated lungs following sodium nitroprusside perfusion under normoxic and hypoxic condition, result in apparent contrast with the hypothesis reported above. However, it is possible that the NO released from sodium nitroprusside might have induced vasodilatation, rapidly improving the blood¯ow and reducing tissue hypoxia, which all would result in down-regulation of VEGF mRNA. In addition, hypoxic responses in lung and renal vessel are often opposite to those of other vessels. Ohigashi et al. (1993) demonstrated that L-NAME inhibited cGMP generation and Epo production in response to hypoxia, and suggested that NO synthesis is essential for hypoxic stimulation of Epo synthetic pathway. Furthermore, Melillo et al. (1995) provided evidence that inducible NOS itself may be a hypoxia inducible gene, regulated by the HIF-1 transcription factor. But mRNA levels of HIF-1 a and b, the subunits of HIF-1, which have been known to be induced in hypoxic condition (Wang and Semenza, 1995) , were not signi®cantly increased in A-172 cells under the conditions reported in this work (unpublished), suggesting that NO might not induce all of the hypoxia inducible genes but might partly mimic to hypoxic stimulation.
Although VEGF is known to be induced by various conditions such as hypoxia and some cytokines including interleukin-1b (IL-1b) (Li et al., 1995) , interleukin-6 (IL-6) (Cohen et al., 1996) , TGF-b (Pertovaara et al., 1994) , and prostaglandin E 2 and E 1 (Harada et al., 1994) , and protein kinase C has been shown to be involved in signal transduction of VEGF expression induced by PDGF (Finkenzeller et al., 1992) , details of the mechanisms of VEGF gene regulation remains to be elucidated. Our results showed that guanylate cyclase is likely to be important for NO-mediated VEGF accumulation (Figure 4) . In this sense, VEGF induction by NO appears to be similar to the pathway of Epo gene induction by NO (Ohigashi et al., 1993) . This is consistent with the similarity in induction of Epo and VEGF genes during hypoxia (Goldberg and Schneider, 1994; Levy et al., 1995) . However Mukhopadhyay et al. (1995) reported that VEGF induction is dependent on c-Src activation and this observation is inconsistent with our present result. NO might take a shorter way the signal transduction pathway to VEGF gene or activate VEGF gene through dierent pathway. 
Materials and methods
Chemicals
RNA extraction and Northern blot analysis
Total RNA from A-172 and HepG2 cells were isolated by the guanidinium thiocyanate extraction method (Chomczynski and Sacchi, 1987) . Equal amount of total RNAs (20 mg/lane) were electrophoresed in a 1% agarose gel containing 6% formaldehyde and transferred to a nylon membrane (Hybond N; Amersham). After u.v. crosslinking, the ®lter was prehybridized for 6 h at 428C in hybridization buer containing 50% deionized formamide, 0.65 M NaCl, 5 mM EDTA (pH 7.6), 0.1% sodium dodecyl sulfate (SDS), 0.1 M piperazine-N',N'-bis (2-ethanesulfonic acid) (pH 6.8), 56Denhardt's solution [0.1% Ficoll 400/ 0.1% PVP/0.1% BSA (fraction V)], and 100 mg/ml denatured salmon sperm DNA, and then hybridized with a probe for 12 h at 428C. As a probe, a 610 bp fragment of VEGF cDNA cloned from human whole brain mRNA was labeled with [a-32 P] dCTP (3000 Ci/mmol), using a random prime labeling kit (Amersham). The ®lter was washed at 578C with 26SSC/0.1% SDS for 1.5 h and exposed to an imaging plate. Radioactivity was then analysed with a Bioimage analyser BAS 2000 (Fuji Photo Film Co., Japan). To evaluate the amount of RNA analysed, the ®lter was rehybridized with a 32 P-labeled cDNA probe of 1.5 kb for human b-actin containing the entire coding region.
mRNA stability assay
The half-life of VEGF mRNA was determined by treating A-172 cells with actinomycin D. A-172 cells were cultured for 6 h with or without SNAP (0.5 mM), then actinomycin D was added to the culture medium (25 mg/ml) to block transcription and promptly returned to the same conditions. The cells were harvested at 0, 4, 8 and 16 h after addition of actinomycin D. Total RNA was prepared and Northern analysis was performed as described. The amount of VEGF mRNA and b-actin mRNA at each time point was quantify after Northern analysis with a Bio-image analyser BAS 2000. The amounts of VEGF mRNA was corrected for loading dierences by amount of the b-actin mRNA.
Western blot analysis of VEGF protein
A-172 cells were seeded onto a 15 cm petridish 16 h before SNAP treatment and added 75 ml of stock solution of SNAP in DMSO or DMSO alone. After incubation of A-172 cells with SNAP, 5 ml of conditioned medium from the cell cultures was harvested and centrifuged to remove cell debris. Heparin-binding proteins were precipitated from the supernatant with 80 ml of heparin-Sepharose (1:1 slurry; Pharmacia) for 2 h at 48C. Heparin-Sepharose beads were precipitated by centrifugation and washed three times with washing buer containing 20 mM TrisHCl, pH 7.5, 300 mM NaCl, 200 mM PMSF, 1 mM DTT, and 1 mM leupeptin. Heparin-Sepharose-bound proteins were extracted by a 3-min incubation in Laemmli's sample buer at 1008C and separated on a 12% sodium dodecyl sulfate-polyacrylamide gel. After transfer to Immobilon membrane (Millipore), VEGF proteins were detected using polyclonal rabbit anti-human VEGF antibody (Santa Cruz Biotechnology) and the bands were visualized by ECL system (Amersham).
